Table 1

Algorithm for treatment changes in the symptom and inflammatory management groups

Increase treatmentNo change in treatmentDecrease treatment
Symptom management group
 Number of major exacerbations (courses of OCS)>1≤1≤1
 SABA usage (times per week)>53–5<3
Inflammatory management group
Sputum eosinophils, %>2.50.1–2.5<0.1
 FENO, ppb (if no sputum sample available)>3022–30<22
  • FENO, exhaled nitric oxide; OCS, oral corticosteroids; SABA, short-acting β agonist.